(Q38785510)

English

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

scientific article published on 05 December 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

phase III clinical trial

0 references

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Josep M. Llovet

19

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Alessandro Granito

object named as

Alessandro Granito

4

0 references

Yi-Hsiang Huang

object named as

Yi-Hsiang Huang

5

0 references

object named as

Ann-Lii Cheng

18

0 references

17

object named as

Masatoshi Kudo

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Gerold Meinhardt

23

object named as

Gerold Meinhardt

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

2

object named as

Shukui Qin

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

14

object named as

Tianqiang Song

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

author name string

Philippe Merle

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

György Bodoky

6

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Marc Pracht

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Osamu Yokosuka

8

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Olivier Rosmorduc

9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Valeriy Breder

10

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

René Gerolami

11

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Gianluca Masi

12

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Paul J Ross

13

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Jean-Pierre Bronowicki

15

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Isabelle Ollivier-Hourmand

16

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Richard S Finn

20

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Marie-Aude LeBerre

21

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Annette Baumhauer

22

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Guohong Han

24

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

RESORCE Investigators

25

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

language of work or name

0 references

publication date

5 December 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

389

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

10064

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

56-66

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932453-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(16)32453-9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38785510&oldid=1786848582"